#USA #New York #Class Action #Intellia Therapeutics #NTLA

Class Action Lawsuit Against Intellia Therapeutics, Inc.

On April 7, 2025, the Gross Law Firm announced a class action lawsuit targeting Intellia Therapeutics, Inc. (NASDAQ: NTLA), focusing on shareholders who acquired shares during a specified class period. Investors are encouraged to consider joining this legal proceeding, which aims to address potential damages incurred due to misleading statements regarding Intellia's clinical operations.

Timeline and Important Dates

The class period spans from July 30, 2024, to January 8, 2025. This crucial timeframe encompasses significant developments within the company, particularly related to its studies on NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-related lung disease. Notably, shareholders purchasing stocks during this period are eligible to join the class action, with a deadline set for April 14, 2025. Therefore, it is vital for concerned shareholders to take prompt action and ensure their involvement.

Allegations Against Intellia

The lawsuit stems from allegations that Intellia’s management lacked transparency with investors about the status of NTLA-3001. It was claimed that the company indicated confidence in maintaining its development timelines, misleading shareholders regarding its clinical trials. However, internal evaluations suggested a declining demand for viral-based therapies, especially as non-viral alternatives became favored for their efficiency and cost-effectiveness.

The case took a decisive turn on January 9, 2025, when Intellia disclosed a complete halt in NTLA-3001 research alongside a significant workforce reduction of 27%. This announcement shocked the market and resulted in a steep drop in Intellia's stock price, plummeting from $12.02 to $10.20 in just two days, highlighting the immediate financial impact of the company's decisions.

Steps for Shareholders

Affected shareholders have several options to participate in the lawsuit. Registering as a participating shareholder grants access to portfolio monitoring tools, which provide ongoing updates throughout the litigation process. Joining the class action does not require aspiring participants to become lead plaintiffs, ensuring a more accessible path to potential recovery for all investors.

It is crucial to file by the April 14 deadline to ensure participation and safeguard individual rights within the class action suit.

Why Choose Gross Law Firm?

The Gross Law Firm has established its reputation as a leading firm specializing in class action lawsuits. With a mission centered on safeguarding investor rights, the firm focuses on holding corporations accountable for any illegal or misleading practices that lead to financial losses for shareholders. Investors who have suffered due to misinformation or neglect from the company can rely on the firm's commitment to seeking restitution and promoting ethical business standards. Their expertise ensures that investors are well-represented and informed throughout the proceedings.

For those interested in taking steps forward, consultation and registration can be facilitated through the firm's website. To prevent the loss of potential recovery, anyone who believes they might be affected should act swiftly.

Contact Information

To learn more about the class action or to register, interested parties can reach the Gross Law Firm via the following:

• - Website: Gross Law Firm Contact
• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903

In summary, the class action lawsuit against Intellia Therapeutics represents a significant opportunity for shareholders to pursue justice and recovery for potential financial losses. With steadfast legal support from the Gross Law Firm, investors can navigate this situation with increased confidence.